Cancer Research Technology

The new firm, created by Syncona and Cancer Research Technology, has raised $17.5 million to support development of individualized therapies targeted to tumor neoantigens.

Biomérieux has been awarded US Patent No. 8,106,172, "Nucleic acid sequences that can be used as primers and probes in the amplification and detection of SARS coronavirus."

In its companion diagnostics development program for an investigational PARP inhibitor oncologic, Pfizer is pursuing methylation-specific biomarkers rather than BRCA gene mutations to help personalize the drug.

MDxHealth will use its DNA methylation platform to identify and develop biomarkers that can predict patient response to a PARP inhibitor under development by Newcastle University, Cancer Research Technology, and Pfizer.

AstraZeneca and Cancer Research UK will contribute a combined £5.6 million ($8.9 million) to the Institute of Cancer Research to discover and develop cancer drugs that target molecular chaperones. AstraZeneca will have an exclusive worldwide license to compounds developed during the collaboration.

A federal grand jury has indicted Elizabeth Holmes and Ramesh Balwani for alleged wire fraud in conjunction with their activities at Theranos.

Nature News reports that some developers are nervous about GitHub's acquisition by Microsoft.

A direct-to-consumer genetic testing company sent out used spit kits, CNBC reports.

In PLOS this week: comparison of commercial bisulfite kits, new method to predict essential proteins, and more